[go: up one dir, main page]

AR041206A1 - Imidazolpiridinas y metodos para preparar y usarlas - Google Patents

Imidazolpiridinas y metodos para preparar y usarlas

Info

Publication number
AR041206A1
AR041206A1 ARP030103249A ARP030103249A AR041206A1 AR 041206 A1 AR041206 A1 AR 041206A1 AR P030103249 A ARP030103249 A AR P030103249A AR P030103249 A ARP030103249 A AR P030103249A AR 041206 A1 AR041206 A1 AR 041206A1
Authority
AR
Argentina
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
heteroaryl
alkoxy
Prior art date
Application number
ARP030103249A
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of AR041206A1 publication Critical patent/AR041206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se presentan compuestos que poseen una alta afinidad por Alk5 y/o Alk4, y pueden ser útiles como antagonistas de los mismos para la prevención y/o tratamiento de numerosas enfermedades, incluyendo desórdenes fibróticos. Reivindicación 1: Uncompuesto de la siguiente fórmula (1) en donde cada uno de X1, X2, X3, y X4 es independientemente seleccionado de entre CRx o N; siempre que sólo dos de entre X1, X2, X3 y X4 puedan ser N de manera simultánea; cada de Y1 e Y2, es independientementeseleccionado de entre CRy o N; siempre que al menos uno de entre Y1 e Y2 sea N; cada R1 es independientemente seleccionado de entre alquilo, alquenilo, alquinilo, alcoxi, acilo, halo, hidroxi, amino, nitro, ciano, guanadino, amidino, carboxi, sulfo,mercapto, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, aminocarbonilo, alquilcarbonilamino, alquilsulfonilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea, sulfamoilo, sulfamida, carbamoilo, cicloalquilo, cicloalquiloxi,cicloalquilsulfanilo, heterocicloalquilo, heterocicloalquiloxi, heterocicloalquilsulfanilo, arilo, ariloxi, arilsulfanilo, aroil, heteroarilo, heteroariloxi, heteroarilsulfanilo, o heteroaroilo; cada R2 es independientemente seleccionado de entrealquilo, alquenilo, alquinilo, acilo, halo, hidroxi, -NH2, -NH(alquil), -N(alquil)2, -NH(cicloalquil), -N(alquil)(cicloalquil), -NH(heterocicloalquil), -NH(heteroaril), -NH-alquil-heterocicloalquilo, -NH-alquil-heteroarilo, -NH(aralquil),cicloalquilo, (cicloalquil)alquilo, arilo, aralquilo, aroilo, heterocicloalquilo, (heterocicloalquil)alquilo, heteroarilo, heteroaralquilo, heteroaroilo, nitro, ciano, guanadino, amidino, carboxi, sulfo, mercapto, alcoxi, cicloalquiloxi,(cicloalquil)alcoxi, ariloxi, arilalcoxi, heterocicloalquiloxi, (heterocicloalquil)alcoxi, heteroariloxi, heteroarilalcoxi, alquilsulfanilo, cicloalquilsulfanilo, (cicloalquil)alquilsulfanilo, arilsulfanilo, aralquilsulfanilo,heterocicloalquilsulfanilo, (heterocicloalquil)alquilsulfanilo, heteroarilsulfanilo, heteroarilalquilsulfanilo, alquilsulfinilo, alquilsulfonilo, aminocarbonilo, aminosulfonilo, alquilcarbonilamino, cicloalquilcarbonilamino,(cicloalquil)alquilcarbonilamino, arilcarbonilamino, aralquilcarbonilamino, (heterocicloalquil)carbonilamino, (heterocicloalquil)alquilcarbonilamino, heteroarilcarbonilamino, heteroaralquilcarbonilamino, alcoxicarbonilaminoalquilamino,(heteroaril)arilcarbonilaminoalquilamino, heteroaralquilcarbonilaminoalquilamino, (heteroaril)arilsulfonilaminoalquilcarbonilaminoalquilamino, arilsulfonilaminoalquilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea, sulfamoilo, sulfamida, ocarbamoilo; m es seleccionado de entre 0, 1, 2, 3, o 4; siempre que cuando m l 2, dos grupos R1 adyacentes pueden unirse entre sí para formar una porción cíclica opcionalmente sustituida de 4 a 8 miembros; n es seleccionado de entre 0, 1, 2, o 3;siempre que, cuando n l 2, dos grupos R2 adyacentes puedan unirse entre sí para formar una porción cíclica opcionalmente sustituida de 4 a 8 miembros; cada uno de Rx y Ry es independientemente seleccionado de entre H, alquilo, alquenilo, alquinilo,alcoxi, acilo, halo, hidroxi, amino, nitro, ciano, guanadino, amidino, carboxi, sulfo, mercapto, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, cicloalquilcarbonilo, (cicloalquil)alquilcarbonilo, aroilo, aralquilcarbonilo,heterocicloalquilcarbonilo, (heterocicloalquil)acilo, heteroaroilo, (heteroaril)acilo, aminocarbonilo, alquilcarbonilamino, (amino)aminocarbonilo, alquilsulfonilaminocarbonilo, alquilsulfonilamino, cicloalquilcarbonilamino, cicloalquilsulfonilamino,(cicloalquil)alquilcarbonilamino, (cicloalquil)alquilsulfonilamino, arilcarbonilamino, arilsulfonilamino, aralquilcarbonilamino, aralquilsulfonilamino, (heterocicloalquil)carbonilamino, (heterocicloalquil)sulfonilamino,(heterocicloalquil)alquilcarbonilamino, (heterocicloalquil)alquilsulfonilamino. heteroarilcarbonilamino, heteroarilsulfonilamino, heteroaralquilcarbonilamino, heteroaralquilsulfonilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea,sulfamoilo, sulfamida, carbamoilo, cicloalquilo, cicloalquiloxi, cicloalquilsulfanilo, (cicloalquil)alquilo, (cicloalquil)alcoxi, (cicloalquil)alquilsulfanilo, heterocicloalquilo, heterocicloalquiloxi, heterocicloalquilsulfanilo,(heterocicloalquil)alquilo, (heterocicloalquil)alcoxi, (heterocicloalquil)alquilsulfanilo, arilo, ariloxi, arilsulfanilo, aralquilo, aralquiloxi, aralquilsulfanilo, arilalquenilo, arilalquinilo, heteroarilo, heteroariloxi, heteroarilsulfanilo,heteroaralquilo, (heteroaril)alcoxi, o (heteroaril)alquilsulfanilo; o una sal farmacéuticamente aceptable o un N-óxido de los mismos.
ARP030103249A 2002-09-06 2003-09-08 Imidazolpiridinas y metodos para preparar y usarlas AR041206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40881202P 2002-09-06 2002-09-06

Publications (1)

Publication Number Publication Date
AR041206A1 true AR041206A1 (es) 2005-05-11

Family

ID=31978685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103249A AR041206A1 (es) 2002-09-06 2003-09-08 Imidazolpiridinas y metodos para preparar y usarlas

Country Status (20)

Country Link
US (1) US20060135517A1 (es)
EP (1) EP1546112A4 (es)
JP (1) JP2006502164A (es)
KR (1) KR20050035296A (es)
CN (1) CN1694871B (es)
AR (1) AR041206A1 (es)
AU (1) AU2003270318B2 (es)
BR (1) BR0314052A (es)
CA (1) CA2497968A1 (es)
EA (1) EA010426B1 (es)
GE (1) GEP20074165B (es)
MX (1) MXPA05002442A (es)
MY (1) MY139566A (es)
NO (1) NO20051493L (es)
NZ (1) NZ539068A (es)
PL (1) PL375691A1 (es)
RS (1) RS20050199A (es)
UA (1) UA80296C2 (es)
WO (1) WO2004021989A2 (es)
ZA (1) ZA200501853B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JP4931589B2 (ja) * 2004-07-02 2012-05-16 正明 松岡 ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
AU2005278292B2 (en) * 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives
CA2578630A1 (en) * 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
JP5206405B2 (ja) * 2005-03-21 2013-06-12 エムイーアイ・ファーマ・インコーポレイテッド イミダゾ［１，２−ａ］ピリジン誘導体：製造および医薬用途
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
US20100166819A1 (en) * 2005-12-22 2010-07-01 Biogen Idec Ma Inc. A Corporation Transforming Growth Factor Modulators
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US8134000B2 (en) 2008-07-14 2012-03-13 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
CA2731323A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
US8759356B2 (en) * 2009-05-19 2014-06-24 Dow Agrosciences, Llc. Compounds and methods for controlling fungi
JP2012528174A (ja) * 2009-05-27 2012-11-12 アボット・ラボラトリーズ キナーゼ活性のピリミジン阻害剤
AU2010259042A1 (en) 2009-06-08 2011-12-15 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
TWI450894B (zh) * 2009-12-18 2014-09-01 Mitsubishi Tanabe Pharma Corp 新穎抗血小板藥
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5959330B2 (ja) * 2011-06-17 2016-08-02 田辺三菱製薬株式会社 新規抗血小板薬
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
JP6426603B2 (ja) 2012-06-26 2018-11-21 ヤンセン ファーマシューティカ エヌ．ベー． 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
EA039595B1 (ru) 2012-10-05 2022-02-15 Кадмон Корпорейшн, Ллк Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
CN104918919A (zh) 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂
RS60371B1 (sr) 2013-03-14 2020-07-31 Brigham & Womens Hospital Inc Sastavi i postupci za ekspanziju i kultivisanje epitelnih matičnih ćelija
ES2625744T3 (es) * 2013-06-04 2017-07-20 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso
US10370371B2 (en) 2013-08-30 2019-08-06 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
PL3240805T3 (pl) 2014-12-15 2025-05-05 The Regents Of The University Of California Dwuswoisty chimeryczny receptor antygenu z bramką alternatywy, reaktywny wobec cd19 oraz cd20
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
US11014980B2 (en) 2015-10-30 2021-05-25 The Regents Of The University Of California Transforming growth factor-beta-responsive polypeptides and their methods for use
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
EP3577116B1 (en) * 2017-02-01 2025-04-23 Changzhou Qianhong Bio-Pharma Co., Ltd Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
CA3076476A1 (en) * 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CN111655260A (zh) * 2017-10-26 2020-09-11 南方研究院 作为TGF-β抑制剂的噁二唑和噻二唑
MX2020007797A (es) * 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
EP3820467A4 (en) * 2018-07-09 2022-05-04 Synthis Therapeutics, Inc. ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
WO2020019108A1 (en) 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CA3109386A1 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Use of 5-fluoro-2-(6-fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine in the treatment of pancreatic cancer
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
WO2023125541A1 (zh) * 2021-12-27 2023-07-06 浙江光昊光电科技有限公司 一种有机电子器件

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) * 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
JP3420751B2 (ja) * 1998-11-03 2003-06-30 グラクソ グループ リミテッド 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
JP4290858B2 (ja) * 2000-06-12 2009-07-08 富士フイルム株式会社 有機電界発光素子
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
TW200417547A (en) * 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
MY139566A (en) 2009-10-30
ZA200501853B (en) 2005-11-30
AU2003270318B2 (en) 2010-01-14
WO2004021989A3 (en) 2004-09-23
US20060135517A1 (en) 2006-06-22
NO20051493D0 (no) 2005-03-21
JP2006502164A (ja) 2006-01-19
RS20050199A (sr) 2007-08-03
NO20051493L (no) 2005-03-21
CA2497968A1 (en) 2004-03-18
PL375691A1 (en) 2005-12-12
CN1694871A (zh) 2005-11-09
WO2004021989A2 (en) 2004-03-18
GEP20074165B (en) 2007-07-25
UA80296C2 (en) 2007-09-10
KR20050035296A (ko) 2005-04-15
EP1546112A2 (en) 2005-06-29
EA200500453A1 (ru) 2005-10-27
BR0314052A (pt) 2005-07-05
MXPA05002442A (es) 2005-09-30
EA010426B1 (ru) 2008-08-29
EP1546112A4 (en) 2006-06-07
AU2003270318A1 (en) 2004-03-29
CN1694871B (zh) 2010-06-16
NZ539068A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
AR041206A1 (es) Imidazolpiridinas y metodos para preparar y usarlas
AR041207A1 (es) Pirazolo piridinas
AR062196A1 (es) Imidazo[4,5-b]pirazinas e imidazo[4,5-b]quinoxalinas, composiciones y metodos
GR3032151T3 (en) Sulphonamide derivatives as aspartyl protease inhibitors
AR042659A1 (es) Derivados de 4-5 diariltiazoles como ligandos de cb-1
AR051587A1 (es) Metodos para tratar lesiones vascularesy dispositivo implantable
CO5370678A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
NZ595000A (en) Imidazo[4,5-c]pyridine derivative for treating viral infections
CA2250840A1 (en) Antivirally active heterocyclic azahexane derivatives
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
ATE522528T1 (de) Virale inhibitoren
BRPI0519759A2 (pt) composiÇÕes farmacÊuticas
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
AR014868A1 (es) UN COMPUESTO DERIVADO DE N,N ( SUSTITUIDO) FENIL (ARILO O HETEROARILO) PROPANAMINA, UNA COMPOSICIoN FARMACÉUTICA, USO DE DICHO COMPUESTO Y UN MÉTODO PARA PREPARARLO.
WO2004050645A8 (en) Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
BR0002518A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
AR047671A1 (es) Compuestos de arilnitrona 2-sustituidos y 4-sustituidos
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
AR019427A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
AR070791A1 (es) Derivados de imidazo[4, 5 - d]piridazina, una composicion farmaceutica que los comprende y su uso en el tratamiento de una infeccion viral mediada por el virus de la hepatitis c.
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure